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Abstract
Background: Formation of tumour cell aggregation/emboli prolongs the survival of circulating tumour cells in the 
circulation, enhances their physical trapping in the micro-vasculature and thus increases metastatic spread of the 
cancer cells to remote sites.
Results: It shows here that the presence of the galactoside-binding galectin-3, whose concentration is markedly 
increased in the blood circulation of cancer patients, increases cancer cell homotypic aggregation under anchorage-
independent conditions by interaction with the oncofetal Thomsen-Friedenreich carbohydrate (Galβ1,3GalNAcα-, TF) 
antigen on the cancer-associated transmembrane mucin protein MUC1. The galectin-3-MUC1 interaction induces 
MUC1 cell surface polarization and exposure of the cell surface adhesion molecules including E-cadherin. The 
enhanced cancer cell homotypic aggregation by galectin-MUC1 interaction increases the survival of the tumour cells 
under anchorage-independent conditions by allowing them to avoid initiation of anoikis (suspension-induced 
apoptosis).
Conclusion: These results suggest that the interaction between free circulating galectin-3 and cancer-associated 
MUC1 promotes embolus formation and survival of disseminating tumour cells in the circulation. This provides new 
information into our understanding of the molecular mechanisms of cancer cell haematogenous dissemination and 
suggests that targeting the interaction of circulating galectin-3 with MUC1 in the circulation may represent an effective 
therapeutic approach for preventing metastasis.
Introduction
Formation of tumour cell aggregation/emboli in the cir-
culation prolongs the survival of tumour cells and allows
their physical trapping in the micro-vasculature and con-
tributes to cancer cell hematogenous dissemination [1,2].
The formation of tumour emboli is heavily regulated by
the expression, availability and activity of the cell surface
adhesion molecules.
Galectin-3 is a multi-functional galactoside-binding
protein that is expressed by many types of human cells. It
is found inside and outside of the cells as well as in the
circulation. Intracellular galectin-3 is an apoptosis inhibi-
tor [3] and mRNA splicing promoter [4] whilst cell sur-
face-associated extracellular galectin-3 acts as an
adhesion molecule in cell-cell interactions [5,6] and pro-
motes cancer progression and metastasis [7,8]. The con-
centration of free circulating galectin-3 is markedly
increased in the sera of patients with breast, colorectal,
lung [9], head and neck [10] cancers and melanoma [11].
Patients with metastatic disease are seen to have higher
concentrations of circulating galectin-3 than those with
localized tumours. Recently, we have shown that the
transmembrane mucin protein MUC1 is an endogenous
ligand of galectin-3 in human colon cancer cells and that
the interaction between MUC1 and galectin-3 occurs via
binding of galectin-3 to the oncofetal Thomsen-Frieden-
reich carbohydrate (Galβ1,3GalNAcα-, T or TF) antigen
on MUC1 [12].
MUC1 is a large and heavily glycosylated transmem-
brane mucin protein that is expressed on the apical sur-
face of normal secretory epithelia [13]. In epithelial
cancer cells, MUC1 is over-expressed [14] and aberrantly
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glycosylated with short oligosaccharides such as Gal-
NAcα- (Tn), sialylated GalNAcα- (sialyl-Tn) and TF anti-
gen [15,16]. On cancer cells, MUC1 also loses its apical
polarization and becomes expressed over the entire cell
surface [17,18]. TF antigen is covered in normal epithe-
lium by extensive glycosylation, sulphation and/or sialyla-
tion but expressed in unsubstituted form by most human
cancer cells [19,20]. The increased expression of MUC1
and the increased occurrence of TF antigen are both
associated, independently, with high metastatic potential
of the cancer cells and poor prognosis of the patients
[21,22]. MUC1 is an extremely elongated molecule which
protrudes over 10 times further from the cell surface than
the typical cell surface adhesion molecules [14] and
therefore influences cell adhesion when is present at high
density at the cell surface [23]. Thus, over-expression of
MUC1 promotes tumour cell release from primary
tumour sites by inhibiting E-cadherin-mediated cell-cell
and integrin-mediated cancer-extracellular matrix inter-
actions [18,24].
We have previously shown that the interaction between
cell surface MUC1 and galectin-3 at concentrations simi-
lar to those found in the sera of cancer patients increases
cancer cell heterotypic adhesion to endothelium as a
result of MUC1 cell surface polarization which leads to
exposure of heterotypic cell-cell adhesion molecules that
are otherwise concealed by elongated structure of MUC1
[12]. As change of MUC1 cell surface localization in
response to galectin-3 binding may also expose the adhe-
sion molecules that are essential to homotypic cancer cell
interactions, we hypothesised that an increased interac-
tion between circulating galectin-3 and cancer-associated
MUC1 expressed on the surface of circulating tumour
cells in cancer patients may promote the formation of
cancer cell aggregates/emboli thus prolongs the survival
of disseminated tumour cells in the circulation and con-
tributes to cancer cell haematogenous dissemination.
We provide evidence in this study showing that the
interaction between cell surface MUC1 and recombinant
galectin-3 at pathologically-relevant circulating galectin-
3 concentrations increases homotypic aggregation of
human colon and breast cancer cells as a result of cell sur-
face clustering of MUC1 and consequent exposure of the
homotypic cell adhesion molecules including E-cadherin.
The galectin-3-MUC-induced cell aggregation increases
the survival of the cancer cells by preventing initiation
cellular anoikis (suspension-induced apoptosis).
Results
Human colon and breast cancer cell-cell homotypic 
aggregation is inhibited by MUC1 expression but restored 
by MUC1-galectin-3 interaction
T o  t e s t  t h e  e f f e c t  o f  M U C 1  e x p r e s s i o n  o n  c a n c e r  c e l l
homotypic aggregation, we first compared the adhesive
properties of human colon cancer HT29 and HT29-5F7
cells. HT29-5F7 is a subpopulation of HT29 cells and was
selected for its resistance to 5-fluorouracil and has much
higher MUC1 expression than the parental HT29 cells
(Fig 1A) [25]. It was found that spontaneous aggregation
of HT29 cells was 2.8-fold greater than that of HT29-5F7
cells (Fig 1B and 1C). Pre-treatment of HT29-5F7 cells
with recombinant galectin-3 at similar circulating galec-
tin-3 concentrations found in the sera of colorectal can-
cer patients [9] resulted in a dose-dependent increase of
HT29-5F7 but not HT29 cell aggregation (Fig 1D). At 1.0
μg/ml, galectin-3 caused a 69% increased aggregation
[169.2 ± 24.7 (mean ± SEM), p < 0.01] of HT29-5F7 but
not HT29 cells (91.4 ± 5.9, p = 0.2) (Fig 1B)
Spontaneous aggregation of HBL-100 human breast
epithelial cells transfected with MUC1-cDNA (HCA1.7+)
(5.1 ± 0.4%) was significantly less compared to MUC1-
negative controls (HCA1.7-) (8.0 ± 0.3, p < 0.001) (Fig 2A
and 2B). Pre-treatment of the cells with galectin-3, at 1.0
μg/ml, caused 36% increased aggregation of HCA1.7+
(136.6 ± 7.0, p < 0.01) but not HCA1.7- cells (94.2 ± 4.2, p
= 0.2) (Fig 2C). The effect of galectin-3 on HCA1.7+ cell
aggregation was dose-dependent (Fig 2D) and was pre-
vented by the presence of 10 μM lactose (Fig 2E). Pre-
treatment of HCA1.7+ cells with streptococcal O-glyca-
nase, that specifically removes the unsubstituted TF
disaccharide, caused a 58% reduction of TF epitope on
MUC1 as assessed by PNA blotting (Fig 3A) and attenu-
ated the galectin-3-induced cell aggregation (Fig 3B).
Thus, expression of MUC1 prevents homotypic cell
aggregation but the aggregation is restored by the interac-
tion of galectin-3 with TF/MUC1.
Galectin-3 and B27.29 anti-MUC1 mAb have similar effects 
on MUC1 cell surface polarization and on epithelial cancer 
cell-cell aggregation
Our previous study demonstrated that B27.29 anti-
MUC1 mAb, directed against the PDTRPAP epitope [26]
within the VNTR region of MUC1, induces MUC1 cell
surface polarization and increases human melanoma cell
adhesion to endothelium [27]. We found here that addi-
tion of B27.29 mAb to HCA1.7+ cells in suspension also
caused a dose-dependent increase in cell aggregation (Fig
4A), regardless of the presence or absence of recombinant
galectin-3 (Fig 4B). When the cell aggregates were further
analysed, it was found that B27.29 mAb not only induced
more cell aggregates but also larger aggregates than
recombinant galectin-3 (data not shown).
Fourteen percent (71/500) of the HCA1.7+ cells
showed spontaneous clustering of MUC1 on the cell sur-
face, when cultured in suspension for 1 hour at 37°C.
After pre-incubation of the cells with 1 μg/ml recombi-
nant galectin-3 or 27.29 mAb for 1 hr at 37°C, 57% (112/
500, P < 0.01) and 93% (133/500, P < 0.01) more cells,Zhao et al. Molecular Cancer 2010, 9:154
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respectively, than the control BSA-treated cells demon-
strated MUC1 cell surface clustering. Introduction of
galectin-3 or mAb B27.29 to the cells at 4°C or to para-
formaldehyde pre-fixed cells had no effect on MUC1
localization and no significant effect on cell aggregation
compared with the control BSA-treated cells (Fig
4C).These results indicate a direct link between discon-
tinuous cell surface localization of MUC1 and the
increased cell aggregation in response to galectin-3 and
B27.29 mAb. In keeping with this, MUC1 was observed
to be absent at the cell-cell contact point within the cell
aggregates in the cells treated either with galectin-3 or
mAb B27.29 (Fig 4D). Thus, polarization of cell surface
MUC1 in response to galectin-3 or anti-MUC1 antibody
binding exposes the smaller cell surface adhesion mole-
cules that increases homotypic cell aggregation (Fig 4E).
The higher cell aggregation induced by B27.29 antibody
than by galectin 3 is in keeping with the notion that a lec-
tin-glycan interaction is weaker than an antibody-antigen
interaction. We have observed that after 48 hr treatment
with galectin-3 under suspension the cell aggregates-
associated MUC1 molecules were still clustered on the
Figure 1 MUC1 expression prevents and MUC1-galectin-3 interaction promotes homotypic aggregation of human colon cancer cells. A: 
Cell surface staining with B27.29 anti-MUC1 antibody followed by analysis with flow cytometry shows higher cell surface MUC1 expression in HT29-
5F7 than in HT29 cells. B: Representative flow cytometry plots from the aggregation assessment of human colon cancer HT29-5F7 and HT29 cells in 
the presence or absence of 1 μg/ml recombinant galectin-3. The top right (blue) in the bivariate correlation plot are the cell population containing 
both DiO- and Dil-labelled cells that are defined in this study as cell aggregates. C: The more strongly MUC1-expressing HT29-5F7 cells show less spon-
taneous cell aggregation than the parental HT29 cells. Data are expressed as mean ± SEM of triplicate determinations from three independent exper-
iments. D: galectin-3 treatment induces a dose-dependent increase of HT29-5F7 but not HT29 cell aggregation. Data are expressed as mean ± SEM 
of triplicate determinations from four independent experiments. **p < 0.01, ***p < 0.001.
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cell surface with some degree of internalization and deg-
radation (Fig 4F).
Involvement of cell surface E-cadherin in galectin-3-
mediated cell aggregation
E-cadherin is known to play a very important role in epi-
thelial cell-cell interactions [18,24]. It was found here that
the presence of 2.5 to 20 μg/ml of MAB1838 anti-E-cad-
herin mAb caused a dose-dependent reduction of the
spontaneous aggregation of HT29 but not HT29-5F7
cells (Fig 5A). However, the presence of 20 μg/ml of this
antibody inhibited HT29-5F7 cell aggregation induced by
galectin-3 (Fig 5B). This indicates the involvement of E-
cadherin in spontaneous aggregation of HT29 cells and in
galectin-3-induced HT29-5F7 cell aggregation. This is
further supported by the discoveries that E-cadherin was
localized at the cell-cell contact points of galectin-3-
mediated cell aggregates (Fig 5C) and suppression of E-
cadherin expression in HT29-5F7 cells by siRNA (Fig 5D
and 5E) resulted in significant reduction of spontaneous
cell aggregation and prevented the increase of cell aggre-
gation in response to galectin-3 (Fig 5F).
We found that HT29 and HT29-5F7 cells have similar
levels of cell surface E-cadherin and similar anti-E-cad-
herin antibody accessibility (Fig 5G). Thus, the inability of
the anti-E-cadherin antibody to prevent HT29-5F7 cell
aggregation is most likely due to a functional "conceal-
ment" of the cell surface E-cadherin in HT29-5F7 cells,
e.g by the presence of adjacent MUC1. The blockade by
the anti-E-cadherin antibody of galectin-3-mediated
HT29-5F7 cell aggregation (Fig 5B) is in support of this.
The fact that the blockade of anti-E-cadherin antibody on
Figure 2 MUC1 expression prevents and MUC1-galectin-3 inter-
action promotes homotypic aggregation of MUC1 positively but 
not negatively transfected human breast epithelial cells. A: Repre-
sentative flow cytometry plots from the aggregation assessment of 
MUC1 positive-transfectants (HCA1.7+) and negative-revertants 
(HCA1.7-) of HBL-100 human breast epithelial cells in the presence or 
absence or 1 μg/ml recombinant galectin-3. B: HCA1.7+ cells show less 
spontaneous cell-cell aggregation than HCA1.7- cells. Data are ex-
pressed as mean ± SEM of triplicate determinations from four indepen-
dent experiments. C: Galectin-3 (1 μg/ml) increases HCA1.7+ but not 
HCA1.7- cell aggregation. Data are expressed as mean ± SEM of tripli-
cate determinations from four independent experiments. D: Galectin-
3 induces dose-dependent aggregation of HCA1.7+ cells. Data are ex-
pressed as mean ± SEM of triplicate determinations from three inde-
pendent experiments. E: The presence of lactose (10 μM) blocks the 
increase of HCA1.7+ cell aggregation induced by 1 μg/ml galectin-3. 
Data are expressed as mean ± SEM of triplicate determinations from 
two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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pression on MUC1. B: Reduction of TF-expression by O-glycanase 
treatment abolishes the effect of galectin-3 (1 μg/ml) on HCA1.7+ cell 
aggregation. Data are expressed as mean ± SEM of triplicate determi-
nations from two independent experiments. *p < 0.05.
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Figure 4 Galectin-3 and B27.29 anti-MUC1 mAb both induce increase of cell aggregation. A: B27.29 mAb induces dose-dependent increase of 
HCA1.7+ cell aggregation. HCA1.7+ cell aggregation was determined after pre-incubation of the cells with or without various concentrations of B27.29 
Mab, 1 μg/ml control mouse immunoglublin or CT-2 anti-MUC1 antibody. Data are expressed as mean ± SEM of triplicate determinations from three 
independent experiments. B: B27.29 mAb increases HCA1.7+ cell aggregation regardless of the presence or absence of recombinant galectin-3. 
HCA1.7+ cell aggregation was determined after pre-incubation of the cells with or without 1 μg/ml recombinant galectin-3 in the presence or ab-
sence of 1 μg/ml B27.29, BSA or control immunoglublin. Data are expressed as mean ± SEM of triplicate determinations from three independent ex-
periments. C: Galectin-3 or B27.29 mAb at 1 μg/ml fails to induce HCA1.7+ cell aggregation at 4°C or to paraformaldehyde-prefixed cells. Data are 
expressed as mean ± SEM of triplicate determinations from four independent experiments. *p < 0.05,**p < 0.01, ***p < 0.001. D: MUC1 localization in 
cell aggregates. Separate aliquots of HCA1.7+ cells pre-labelled with DiO (green) or DiI (red) were mixed in the presence of 1 μg/ml galectin-3 or B27.29 
mAb and incubated for 1 hr at 37°C before fixation and subsequent analysis of MUC1 localization by immunohistochemistry. Representative images 
of the MUC1 localization in cell aggregates are shown. F: localization of the cell aggregates-associated MUC1 (green) after treatment of the cells with 
1 μg/ml galectin-3 for 48 hr under suspension (red: cell nucleuses). Bar = 10 μm.
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Figure 5 Involvement of cell surface E-cadherin in galectin-3-induced cell aggregation. A: The presence of anti-E-cadherin antibody reduces 
spontaneous aggregation of HT29 but has little effect on aggregation of HT29-5F7 cells. Data are expressed as mean ± SEM of triplicate determinations 
from three independent experiments. B: Anti-E-cadherin antibody at 20 μg/ml prevents HT29-5F7 cell aggregation-induced by (1 μg/ml) galectin-3. 
Data are expressed as mean ± SEM of triplicate determinations from three independent experiments. C: E-cadherin localization in single cells and cell 
aggregates. HT29-5F7 cells released by NECDS and labelled separately with DiO and DiI were mixed in the presence or absence of galectin-3 for 1 hr 
at 37°C. The cells were fixed, probed with mAb B27.29 anti-MUC1 or anti-E-cadherin and fluorescent-labelled secondary antibody and analysed by 
fluorescent microscopy. E-cadherin shows localization/accumulation at the cell-cell contact points (arrowed) in the cell aggregates. D: Western blot 
showing that transfection of HT29-5F7 cells with siRNA for E-cadherin suppresses E-cadherin expression. E: E-cadherin immunohistochemistry shows 
marked reduction of the cell surface E-cadherin (green) in HT29-5F7 cells after treatment with E-cadherin siRNA for 72 hr (red: cell nucleus). F: SiRNA-
mediated knock-down of E-cadherin expression prevents galectin-3-mediated HT29-5F7 cell aggregation. Data are expressed as mean ± SEM of trip-
licate determinations from three independent experiments. G: flow cytometry analysis of HT29 and HT29-5F7 cells stained with the MAB1838 anti-E-
cadherin antibody show similar E-cadherin cell surface expressions. Open histogram: E-cadherin; shaded histogram: immunoglobulin isotype control.
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galectin-3-mediated aggregation is only partial implies
the likely involvement of other cell surface adhesion mol-
ecules, which, like E-cadherin, may be exposed following
MUC1 polarization in response to galectin-3 binding.
Galectin-3-induced cell aggregation allows cells to avoid 
initiation of anoikis
Nearly 4-fold more cells in the aggregated cell population
obtained from the galectin-3-treated cells were viable
than those obtained from the BSA-treated controls after
48 hr culture of the cells under suspension conditions (Fig
6A). This indicates that the increase of cell aggregation in
response to galectin-3 greatly enhances the survival of the
cells under anchorage-independent conditions. A modest
36% increase of the cell viability was also observed in the
cell population that passed through the 40 μm Cell
Strainers (referred to as "Strained" cells in Fig 6) from the
galectin-3-treated cells compared with the BSA-treated
controls. As HT29-5F7 cells are 15-20 μm in diameter, it
is possible that this small increase is contributed by the
inclusion of small cell aggregates, e.g. those formed by 2
or 3 cells, in this cell population. Many small cell aggre-
gates were indeed observed in this population by micros-
copy (not shown).
We found that the presence of MAB1838 anti-E-cad-
herin antibody, which prevented galectin-3-induced cell
aggregation (Fig 5B), completely inhibited galectin-3-
mediated increase of the survival of the cell aggregates
(Fig 6B). This suggests that cell surface E-cadherin is crit-
ically involved in galectin-3-mediated cell aggregation
and survival under anchorage-independent condition.
Assessments of anoikis showed no significant differ-
ence between the two strained (single) cell populations
obtained from galectin-3-treated and BSA-treated con-
trols within 48 hr culture of the cells under suspension
conditions (Fig 6C and 6E). However, significantly fewer
cells in the population of cell aggregates obtained from
the galectin-3-treated cells were undergoing anoikis than
from the BSA-treated controls (Fig 6D and 6E). A 20%
(70.0 ± 0.4% vs 56.1 ± 1.8%, p = 0.02), 65% (82.8 ± 1.4% vs
28.7 ± 8.0%, p = 0.0001) and 29% 63.4 ± 5.9% vs 44.9 ±
6.2%, p = 0.02) reduction of anoikis were seen in the cell
aggregates obtained from the galectin-3 treated than
from the BSA-treated control cells after 12, 24 and 48 hr,
respectively (Fig 6D). This indicates that the galectin-3-
induced cell aggregation is associated with resistance of
those cells to anoikis initiation.
Discussion
This study shows that the presence of galectin-3 at patho-
logically-relevant circulating galectin-3 concentrations
increases cancer cell homotypic aggregation by interac-
tion with cancer-associated MUC1 that expresses the TF
disaccharide. The interaction between galectin-3 and
MUC1 causes MUC1 cell surface clustering and exposes
smaller cell surface adhesion molecules including E-cad-
herin. The galectin-3-MUC1-induced cell aggregation
enhances the survival of the cells under anchorage-inde-
pendent conditions by preventing initiation of cellular
anoikis. These discoveries have important implications
for our understanding of the molecular mechanisms that
underlie cancer metastasis.
Survival of tumour cells in the blood/lymphatic circula-
tion is crucial in cancer cell metastatic spread [1,2]. Pro-
longing the survival of disseminating tumour cells in the
circulation directly increases metastasis [28]. Cells in
aggregated form have been shown to have a much higher
survival rate in the circulation than single cells [29,30].
Thus, an increase of tumour cell aggregation as a result of
the increased interaction between circulating galectin-3
and cancer-associated MUC1 in cancer patients provides
a survival advantage to the disseminating tumour cells in
the circulation. Our results have shown that the
enhanced survival of the tumour cells under anchorage-
independent conditions by the galectin-3-MUC1 interac-
t i o n  i s  a s s o c i a t e d  w i t h  a n  e n h a n c e d  a b i l i t y  o f  t h e  c e l l
aggregates to escape initiation of anoikis. Anoikis is a spe-
c i f i c  t y p e  o f  a p o p t o t i c  p r o c e s s  i n d u c e d  b y  l o s s  o f  c e l l
adhesion or inadequate cell-matrix interactions [31] and
has been proposed to be the dominant mechanism in
removing disseminating tumour cells from the circula-
tion [32]. Resistance to anoikis is considered to be a hall-
mark of metastatic cancer cells [33]. As survival of the
tumour cells in the circulation and being eventually able
to produce metastasis at remote site occur only in less
than 1 in 10,000 of the invaded cells [29,34], the enhanced
survival of the disseminating tumour cells by the galectin-
3-MUC1 interaction may have profound consequences
on the metastatic potential of the cancer cells. The dis-
covery by Topal et al [35] that intraportal injection of
aggregated DHD/K12/TRb colon cancer cells into synge-
neic BD IX rats produces over 4-times more liver metas-
tases than injection with the same numbers of single cells
is in consistence with this conclusion.
Furthermore, mechanical as well as "seed-soil" compat-
ibility factors are both believed to contribute to the ability
of specific types of cancer cells to spread to various target
organs [1,36]. It is thought that the initial docking of spe-
cific cancer cells to the target organ is predominantly
controlled by mechanical factors and that this is then fol-
lowed by regulation of specific cell adhesion molecules
on the cell surface. Thus, an increase of tumour cell
homotypic aggregation as a result of the increased inter-
action between circulating galectin-3 and cancer-associ-
ated MUC1 in the bloodstream of cancer patients is likely
to enhance physical trapping of the circulating tumour
cells in the microvasculature at target organ and this also
enhances metastasis.Zhao et al. Molecular Cancer 2010, 9:154
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Figure 6 Galectin-3-induced cell aggregation enhances cell survival by avoiding initiation of anoikis. A: Galectin-3-induced cell aggregation 
is associated with increased survival of the cells under anchorage-independent conditions. HT29-5F7 cells treated with or without 1 μg/ml galectin-
3 or BSA for 1 hr followed by culture of the cells in suspension for 3 days at 37°C. After separation of the cells by cell strainers, the viability of the strained 
(single) cells and cell aggregates was assessed. The data are presented as mean ± SEM of triplicate determinations from two independent experi-
ments. B: The presence of 20 μg/ml anti-E-cadherin antibody inhibited galectin-3-mediated increase of survival of HT29-5F7 cell aggregates. The data 
are presented as mean ± SEM of triplicate determinations from two independent experiments. C and D: Galectin-3 treatment has no effect on anoikis 
of the single cells (C) but significant reduction of anoikis of the cell aggregates (D). Anoikis was assessed by Annexin-V cell surface binding after treat-
ment of the cells with galectin-3 and subsequent separation of the single cells and cell aggregates. The data are presented as mean ± SEM of triplicate 
determinations from two independent experiments. E. Representative flow cytometry plots from the anoikis assessments of HT29-5F7 cells in the 
presence of 1 μg/ml galectin-3 or BSA for 48 hr at 37°C. Annexin-V positive and PI negative (early apoptotic, at the bottom right in the bivariate cor-
relation plot) and Annexin-V positive and PI positive (late apoptotic, at the top right in the correlation plot) cells are considered as apoptotic cells.
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It has been shown previously that cell surface-associ-
ated galectin-3 acts as a cell adhesion molecule and
increases cancer cell homotypic aggregation by interac-
tion with TF antigen expressed by unknown cell surface
molecules on adjacent cells under anchorage indepen-
dent conditions [6,37]. As cell surface-associated galec-
t i n - 3  i s  r e l a t i v e l y  s m a l l  i n  s i z e ,  i t  i s  l i k e l y  t h a t  s u c h
interaction may occur only after MUC1 cell surface
polarization and exposure of the cell surface-associated
galectin-3. It should be noted that clustering of the galec-
tin cell surface receptors in response to galectin binding
is probably not rare and has been shown to occur in some
other cells types such as T cells [38,39]. Although the
mechanism of galectin-ligand clustering remains unclear,
clustering of galectin-3 ligands has been shown to
enhance its binding affinity by as much as 10,000-fold
[40].
It should be noted that HT29-5F7 cells also express
mRNAs for secreted MUC5AC and MUC5B mucins
(with MUC5B the most highly expressed) and transmem-
brane MUC1 and MUC3 mucins (with MUC1 the most
highly expressed) [25]. Although it is unknown whether
the transmembrane MUC3 also carries the TF structure
and a similar mechanism of interaction between galectin-
3 and MUC3 exists, the contribution of such an interac-
tion to galectin-3-mediated cell aggregation in those cells
is likely to be much less than that of the galectin-3-MUC1
interaction as the level of MUC1 expression in these cells
is much greater than for MUC3.
Thus, the interaction between circulating galectin-3
and TF-expressing MUC1 on the surface of disseminating
cancer cells promotes cell aggregation and embolus for-
mation and enhances survival of disseminating tumour
cells in the circulation. This, together with our earlier
reports showing an enhanced cancer cell-endothelial
adhesion also resulting from the galectin-3-MUC1 inter-
action [12,27], indicates that the increased circulation of
galectin-3 in the bloodstream of cancer patients pro-
motes several important steps of the metastatic cascade.
The reduction of metastasis-associated survival of nude
mice intravenously injected with galectin-3-pretreated
than untreated MUC1-expressing human melanoma cells
observed in our earlier study [27] likely represents the
consequence of galectin-3-MUC1 interaction on cancer
cell heterotypic adhesion to endothelium as well as on
cancer cell homotypic aggregation. This study provides
new information into our understanding of the molecular
mechanisms of cancer cell haematogenous dissemination
and further highlights the functional importance of
change of the cell surface glycosylation in cancer progres-
sion. It also implies that targeting the interaction of circu-
lating galectin-3 with MUC1 in the circulation may
represent an effective therapeutic approach for prevent-
ing metastasis.
Materials and methods
Materials
Recombinant full-length human galectin-3 and monoclo-
nal antibody (mAb) against E-cadherin (MAB1838) were
from R&D Systems (Abingdon, UK). B27.29 anti-MUC1
mAb was kindly provided by Dr. Mark Reddish (Biomira
Inc, Canada). CT-2 anti-MUC1 cytoplasmic tail antibody
was from NeoMarkers (Fremont CA). Biotin-conjugated
peanut agglutinin (PNA) was purchased from Vector
Laboratories Ltd (Peterborough, UK). Streptococcus
pneumoniae  Endo-N-acetyl-galactosaminidase (EC
3.2.1.97), O-glycanase, was obtained from Prozyme Inc
(Oxford, UK). The Non-Enzymatic Cell Dissociation
Solution (NECDS) was from Sigma. The Vybrant DiO
and DiI Cell-labelling Solutions were from Molecular
Probes (Cambridge, UK).
Cell lines
Human colon cancer HT29 and HT29-5F7 cells were cul-
tured as previously described [12]. Human colon cancer
HT29-5F7 cells were kindly provided by Dr. Thecla
Lesuffleur (INSERM U560, Lille, France). MUC1 trans-
fection of HBL-100 human breast epithelial cells with full
l e n g t h  c D N A  e n c o d i n g  M U C 1  r e s u l t e d  i n  t h e  M U C 1
positive transfectants HCA1.7+ and the subsequent bulk
selection of the MUC1 negative revertants HCA1.7- were
as described previously [18].
Cell aggregation
Subconfluent cells were released from the culture plates
with NECDS (which releases the cells while keeping the
cell membrane proteins intact) and were dispersed in
serum-free DMEM containing 0.5 mg/ml bovine serum
albumin (BSA). Two 0.5 ml (1×106 cells) aliquots of the
cell suspension were incubated, separately, with 5 μl/ml
DIO and DiI Cell Labelling Solution for 30 min at 37°C.
The DIO- and DiI-labelled cells were then mixed in the
presence or absence of recombinant galectin-3, antibod-
ies or lactose in DMEM in a rotating incubator (Julabo
lab GMBH, Seelbach, Gemerney) at 100 rpm/min at 37°C
for 1 hr followed by analysis with flow cytometry (Bec-
ton-Dickinson FACSVantage SE). Cells labelled only with
DiI or DiO were used to identify the position of DiO-
(upper-left panel) and DiI-(bottom-right panel) labelled
cell populations in the bivariate correlation plot and cell
populations containing both DiO and DiI fluorescence
(top-right panel) in the correlation plot were defined as
cell aggregates (Fig 1A).
This method measures cell aggregates containing both
DiO- and DiI-labelled cells and does not include cell
a g g r e g a t e s  f o r m e d  o n l y  b y  D I O -  o r  D i I - l a b e l l e d  c e l l s .
Although this may underestimate the total cell aggre-
gates, it provides a more accurate assessment of the effect
of exogenous galectin-3 by reducing the variations henceZhao et al. Molecular Cancer 2010, 9:154
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the experimental errors due to the differences of initial
existing numbers of cell aggregates in each individual
assessment.
Reduction of TF expression by O-glycanase treatment
HCA1.7+ cells (105 cells) were incubated with 0.02U/ml
O-glycanase for 2 hr at 37°C. The cells were either lysed
directly with SDS-sample buffer for blotting with PNA or
labelled with DiO and DiI and incubated with recombi-
nant galectin-3 for 1 hr at 37°C before the cell aggregation
assessments.
Electrophoresis and lectin/immunoblotting
SDS-PAGE (4% running gel and 3.5% stack gel for MUC1
blotting and 10% running gel and 4% stack gel for E-cad-
herin blotting) electrophoresis and immune/lectin blot-
ting were performed as previously described [12].
MUC1 cell surface localization
Cells released with NECDS were labelled, separately, with
DiO and DiI as described above. Two equal cell popula-
tions (5×105) of the labelled cells were mixed in the pres-
ence or absence of 1 μg/ml galectin-3, B27.29 antibody or
BSA for 1 hr at 37°C. The cell suspensions were applied to
poly-lysine coated slides, fixed with 2% paraformaldehyde
for 15 min, blocked with 5% normal goat serum for 0.5 hr,
probed with B27.29 anti-MUC1 antibody (1:2,000 dilu-
tion in 1% goat serum/PBS) and followed by fluorescent-
labelled secondary antibody (1:400 dilution in 1% goat
serum/PBS). The slides were blinded and the number of
cells lacking a continuous rim of MUC1 or the number of
small or large aggregates in 500 adjacent cells in ran-
domly selected low power fields was counted using an
Olympus B51 fluorescent microscope with 20× objective.
In some experiments, HT29 or HT29-5F7 cells released
by NECDS were fixed with 2% paraformaldehyde for 15
min, blocked with 5% normal goat serum for 0.5 hr,
probed with B27.29 anti-MUC1 antibody (1:2,000 dilu-
tion in 1% goat serum/PBS) and followed by analysis of
the MUC1 cell surface expression with flow cytometry.
In some other experiments, HT29-5F7 cells released by
NECDS were treated with galectin-3 for 1 hr at 37°C
before introduced and cultured in poly-HAMA-coated
plates for 48 hr. The cells were then fixed with 2% para-
formaldehyde for 15 min, blocked with 5% normal goat
serum for 0.5 hr, probed with B27.29 anti-MUC1 anti-
body (1:2,000 dilution in 1% goat serum/PBS) and the
MUC1 cell surface localization was observed under fluo-
rescent microscope.
E-cadherin cell surface expression
Cells released with NECDS were fixed 2% paraformalde-
hyde for 15 min, blocked with 5% normal goat serum for
0.5 hr, incubated with anti-E-cadherin antibody (1:1000
dilution in 1% goat serum/PBS) or isotype control immu-
noglobulin and followed with fluorescent-conjugated sec-
ondary antibodies (1:400 dilution in 1% goat serum/PBS).
The cell surface expression of E-cadherin was analysed by
flow cytometry.
siRNA E-cadherin transfection
HT29-5F7 cells were treated with commercially available
siRNA constructs (100 nM) against E-cadherin or scram-
bled control non-targeting siRNA (siCONTROL non-tar-
geting siRNA, Dhamacon) for 48 hr at 37°C. The cells
were either lysed and the expressions of E-cadherin was
analysed by immunoblotting or the cells were labelled
w i t h  D i O  a n d  D i I  f o l l o w e d  b y  t h e  a s s e s s m e n t  o f  c e l l
aggregation in the presence or absence of 1 μg/ml galec-
tin-3 as described above.
In some experiments, the HT29 cells were seeded in
24-well plates with glass coverslips inserted for 18 hr at
37°C before treatment of the cells without or with E-cad-
herin siRNA or non-targeting control siRNA for 48 to 72
hr. The cells were then fixed with 2% paraformaldehyde
for 15 min, blocked with 5% normal goat serum for 0.5 hr,
incubated with anti-E-cadherin antibody (1:1000 dilution
in 1% goat serum/PBS) for 1 hr. After application of fluo-
rescent-conjugated secondary antibodies (1:400 dilution
in 1% goat serum/PBS), the cell surface expression of E-
cadherin was observed under fluorescent microscope.
Cell viability and anoikis in strained and aggregated cells 
under anchorage-independent condition
The cells were cultured in 96 or 24 well plates that were
coated twice with 200 μl/well (96-well plates) or 5 ml/well
(6-well plates) of 10 mg/ml poly-2-hydroxyethyl meth-
acrylate (poly-HEMA, Sigma) in 95% ethanol over night
at room temperature. After washing, the cells were
treated with 1 μg/ml recombinant galectin-3 or BSA
under suspension culture in serum-free medium for 6 to
48 hr at 37°C. The cells in suspension were collected and
passed three times through a 40-μm cell strainer (BD Bio-
sciences). The viability of the cells that did (strained) and
did not (aggregates) pass through the strainers was both
measured by the CellTiter-Glo® Luminescent Cell Viabil-
ity Assay (Promega).
For the measurement of cellular anoikis, after separa-
tion of the cells by cell strainers, the strained cells and cell
aggregates were resuspended in 0.05% trypsin in PBS and
the apoptotic cells were measured by FITC-Annexin-V
cell surface binding with a FITC-Annexin-V Apoptosis
Detection Kit (Cambridge Biosciences, Cambridge, UK)
by flow cytometry as the manufacture's instructions.
Statistical analysis
The statistical analyses were performed using the
unpaired t test for single comparison, one-way analysis of
variance (ANOVA) followed by Newman and Keuls testZhao et al. Molecular Cancer 2010, 9:154
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for multiple comparisons or Chi-Square test (StatsDirect
for Windows, StatsDirect Ltd; Sale, UK) where appropri-
ate. Differences were considered significant when p <
0.05.
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